Accelerant Holdings
No enriched coverage for $ARX in the last 7 days.
No SEC Form 4 filings for $ARX in the last 30 days.
See all $ARX insider activity →Aroa Biosurgery (ARX) signed an exclusive U.S. co-promotion deal with Mölnlycke Healthcare for Endoform, effective 2026. Aroa retains ownership and manufacturing; FY27 revenue and EBITDA guidance remain unchanged.
Analysts downgraded several companies: Roth Capital cut SoundThinking (SSTI) to Neutral with a $9 target, Citigroup downgraded Moderna (MRNA) to Sell with an $80 target, TD Cowen downgraded Accelerant (ARX) to Hold with a $20.25 target, Barclays downgraded Mobileye (MBLY) to Equal-Weight with a $9 target, and Citigroup downgraded Dow (DOW) to Neutral with a $30 target.
Analysts updated price targets for several companies. Piper Sandler raised Microsoft's target to $610, maintaining an Overweight rating. Other notable changes include Carmax, Accelerant, Jack Henry, Moderna, Grocery Outlet, Hinge Health, Aytu Biopharma, NetApp, and Ferrari.
Recent ARX coverage spans financial news, mergers & acquisitions and corporate actions.
The partnership may modestly boost sales but guidance unchanged suggests limited immediate price impact.
Downward pressure as rating is reduced and target lowered.
Target cut signals bearish outlook.
Vote locked at 82% reduces execution risk.
Downgrade may limit upside.
AlphAI scores every news story that mentions ARX with an AI model for sentiment and relevance, and aggregates insider trades from Accelerant Holdings's SEC EDGAR Form 4 filings. Figures refresh continuously.
Aroa Biosurgery (ARX) signed an exclusive U.S. co-promotion deal with Mölnlycke Healthcare for Endoform, effective 2026. Aroa retains ownership and manufacturing; FY27 revenue and EBITDA guidance remain unchanged.
1 min readAnalysts downgraded several companies: Roth Capital cut SoundThinking (SSTI) to Neutral with a $9 target, Citigroup downgraded Moderna (MRNA) to Sell with an $80 target, TD Cowen downgraded Accelerant (ARX) to Hold with a $20.25 target, Barclays downgraded Mobileye (MBLY) to Equal-Weight with a $9 target, and Citigroup downgraded Dow (DOW) to Neutral with a $30 target.
2 min readAnalysts updated price targets for several companies. Piper Sandler raised Microsoft's target to $610, maintaining an Overweight rating. Other notable changes include Carmax, Accelerant, Jack Henry, Moderna, Grocery Outlet, Hinge Health, Aytu Biopharma, NetApp, and Ferrari.
2 min readBASF proposed a takeover of Evonik, reflecting defensive consolidation in Europe's chemical sector. Other notable deals include Aquarian's bid for Brighthouse Financial with a 31.4% spread, Thoma Bravo's offer for Accelerant Holdings, and Merck's potential acquisition of Bio-Techne. Bullish's $4.2B deal for Equiniti highlights tokenization trends. Spreads vary, signaling different risk profiles.
3 min readStifel upgraded Microsoft (MSFT) to Buy with a $575 price target, citing sustained revenue growth. Susquehanna upgraded RXO Inc. (RXO) to Neutral with a $19 target. JPMorgan upgraded Graphic Packaging (GPK) to Overweight with an $11.50 target. RBC upgraded Lakefront Biotherapeutics (LKFT) to Outperform with a $45 target. Guggenheim upgraded Editas Medicine (EDIT) to Buy with a $5 target. Wedbush downgraded Compass Therapeutics (CMPX) to Neutral with a $1 target.
2 min readAccelerant Holdings (ARX) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Accelerant Announces Expiration of “Go-Shop” Period ATLANTA—(BUSINESS WIRE)— Accelerant Holdings (NYSE: ARX) (“Accelerant”), the data-driven risk exchange platform transforming the specialty insurance marketplace through the Accelerant Risk Exchange, today announced
2 min readShell PLC (LON: SHEL) and ARC Resources Ltd. (ARX) have agreed to merge, with ARC Resources shares to be exchanged for Shell shares and cash. The deal, approved by shareholders and regulators, is expected to close on September 2, 2026, leading to ARC Resources' delisting and removal from the S&P/TSX Composite Index.
1 min readMultiple Canadian-listed energy and mining stocks hit 52-week highs. ARC Resources reached $33.74; it reported Q2 net income of $353M vs $396.1M a year earlier. Condor Energies rose to $4.22 on a 17,925 boe/d production record. Cenovus hit $44.68 after Q2 results and raised guidance. Other names cited include K2 Gold, MiniLuxe, P2 Gold, ROK Resources, Surge, Tidewater Midstream, Whitecap and Yangarra.
4 min readAccelerant Holdings (ARX) agreed to be acquired by Thoma Bravo in an all-cash deal valuing it at over $4 billion, about a year after its July 2025 IPO. ARX shares rose nearly 44% on Aug. 13, 2026. Class A and B holders receive $20.25 per share. Q2 2026 revenue was $356.9 million (+62.9% YoY) and net income $80 million.
6 min readThe article lists recent insider sales for four Canadian-listed stocks. It reports board member Merfyn Roberts sold AEM shares, CEO Corey Ruttan sold ALV shares, and CEO Aurora Davidson sold ARG shares. For Amerigo Resources, shares were up nearly 70% YTD and hit an intraday record $8.48 on Aug. 11, with dividends tied to copper prices, according to the company.
3 min read
